In a nation where millions of Americans ration life-saving medications due to staggering costs, and communities yearn for stable, high-paying jobs, one pharmaceutical giant is stepping up with a groundbreaking plan. AstraZeneca, a global leader in healthcare, has struck a historic agreement with
I'm thrilled to sit down with Ivan Kairatov, a renowned expert in biopharma with a wealth of experience in research and development, particularly in the rapidly evolving field of cell and gene therapies (CGTs). With his deep knowledge of technology and innovation in the industry, Ivan offers unique
In an era where healthcare is increasingly moving beyond the walls of traditional clinics and hospitals, Hydreight Technologies Inc. (HYDRF) is emerging as a game-changer in the telehealth and direct-to-consumer (DTC) healthcare sectors. With a striking 33% year-over-year revenue surge in the first
Imagine a diagnosis so devastating that it offers a median survival of just one year, primarily striking children and young adults with little hope for effective intervention. Diffuse midline glioma with an ### K27M mutation, an ultra-rare and aggressive brain cancer, affects roughly 2,000
In a landscape where over 50% of pharmaceuticals distributed in the US are manufactured overseas, the fragility of the drug supply chain has become a pressing concern for national health security, prompting urgent action. Imagine a scenario where a global crisis disrupts access to essential
In a landscape where economic volatility often shakes investor confidence, Becton Dickinson (BDX) has emerged as a standout performer, recently revising its full-year earnings outlook upward with an adjusted diluted EPS guidance of $14.30 to $14.45, reflecting a robust 9.4% growth at the midpoint.
